Understanding how a new drug can selectively fight childhood cancer cells
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Looking at how brain tumours hijack immune cells, forcing them to support cancer growth instead of fighting it.
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.
Understanding what information patients and families want, at what points in their cancer journey.
Gathering data to uncover how childhood cancer and its treatment impacts survivors long-term quality of life.